Doravirine is a novel HIV-1 nonnucleoside reverse transcriptase inhibitor with IC50 values of 12, 9.7, and 9.7 nM against the wild type (WT) and K103N and Y181C reverse transcriptase (RT) mutants, respectively, in a biochemical assay. It is highly specific with minimum off-target activities.

Doravirine is a novel HIV-1 nonnucleoside reverse transcriptase inhibitor with IC50 values of 12, 9.7, and 9.7 nM against the wild type (WT) and K103N and Y181C reverse transcriptase (RT) mutants, respectively, in a biochemical assay. It is highly specific with minimum off-target activities.

Vadadustat (AKB-6548, B-506, PG-1016548) is a novel, titratable, oral HIF-PH inhibitor.

Vadadustat (AKB-6548, B-506, PG-1016548) is a novel, titratable, oral HIF-PH inhibitor.

Gadoxetate is a paramagnetic gadolinium-containing contrast agent in which its salt form, gadoxetate disodium, is used for intravenous injection.

Fluticasone furoate (GW685698) is an inhaled corticosteroid/long-acting beta-agonist combination with a prolonged bronchodilator duration of action. It is used for the treatment of non-allergic and allergic rhinitis administered by a nasal spray.

Fluticasone furoate (GW685698) is an inhaled corticosteroid/long-acting beta-agonist combination with a prolonged bronchodilator duration of action. It is used for the treatment of non-allergic and allergic rhinitis administered by a nasal spray.

Uridine triacetate (Vistonuridine, PN401) is an orally active prodrug of the naturally occurring nucleoside uridine. It is used for the treatment of hereditary orotic aciduria (Xuriden), or for the emergency treatment of fluorouracil or capecitabine overdose or toxicity.

Uridine triacetate (Vistonuridine, PN401) is an orally active prodrug of the naturally occurring nucleoside uridine. It is used for the treatment of hereditary orotic aciduria (Xuriden), or for the emergency treatment of fluorouracil or capecitabine overdose or toxicity.

Phosphoethanolamine (PE) is a phosphomonoester metabolite of the phospholipid metabolism.